AACR 2024 Highlights
Review presentations and information shared by Dana-Farber physician-scientists at the 2024 American Association of Cancer Research (AACR) Annual Meeting held April 5-10, San Diego, CA.
Robert Haddad, MD Discusses Head and Neck Cancer Research at AACR24
Important IMvoke010 trial could shape future research in immunotherapy in locally advanced head & neck cancer after results of 1st phase III study in adjuvant therapy don't meet event-free survival endpoint. Dana-Farber's Robert Haddad, ...
Medical Oncology
Pasi Jänne, MD, PhD Discusses Lung Cancer data at AACR24
Dana-Farber's Pasi Jänne, MD, PhD, reports on ctDNA with an EGFR mutation in FLAURA2 trial. The new data shows patients whose blood tested positive before therapy for tumor cell DNA with EGFR mutations stood to gain the most from combination therapy.
Medical Oncology
Rebecca Porter, MD, PhD Discusses Endometrial Cancer Research at AACR24
Dana-Farber's Rebecca Porter, MD, PhD, says antibody-drug conjugate combined with immunotherapy had impressive overall response rate in 16 patients with a rare subtype, but more research is needed.
Medical Oncology
Cami Christoper, MPH Discusses Cancer Survivorship at AACR24
A study at AACR24 suggests a program of moderate-to-vigorous aerobic and resistance exercise can improve a key aspect of heart function in survivors of breast, prostate, and colorectal cancer. Dana-Farber's Cami Christopher, MPH, explains more in this video.Press Releases
Follow us on X (formerly Twitter)
- @DanaFarber Cancer Institute - Information on our expert cancer care and advanced research
- @DanaFarberNews - Your source for Dana-Farber news